Adosterol: A sterol usually substituted with radioactive iodine. It is an adrenal cortex scanning agent with demonstrated high adrenal concentration and superior adrenal imaging. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71738 |
| CHEMBL ID | 2110976 |
| SCHEMBL ID | 10034113 |
| MeSH ID | M0000475 |
| Synonym |
|---|
| np-59 |
| adosterol |
| (3s,6r,8s,9s,13r,14s,17r)-6-(iodomethyl)-13-methyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol |
| h2m0wi52mc , |
| 55623-03-5 |
| 6-iodomethylnorcholesterol |
| 6beta-iodomethyl-19norcholest-5(10)-en-3beta-ol |
| 19-norcholest-5(10)-en-3-ol, 6-(iodomethyl)-, (3beta,6beta)- |
| unii-h2m0wi52mc |
| iodine norcholesterol (131i) |
| norcholestenol iodomethyl, i-131 |
| np-59 i-131 |
| iodinated (131i) norcholesterol |
| SCHEMBL10034113 |
| j397.921k , |
| iodine (131 i) norcholesterol |
| CHEMBL2110976 |
| 6.beta.-iodomethyl-19-norcholest-5(10)-en-3.beta.-ols |
| (3.beta.,6.beta.,17.alpha.)-6-(iodomethyl)-17-((2s)-6-methyl-2-heptanyl)estr-5(10)-en-3-ol |
| (3s,6r,8s,9s,13r,14s,17r)-6-(iodomethyl)-13-methyl-17-(6-methylheptan-2-yl)-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta(a)phenanthren-3-ol |
| norcholestenol iodomethyl |
| 19-norcholest-5(10)-en-3-ol, 6-(iodomethyl)-, (3.beta.,6.beta.)- |
| DTXSID40897512 |
| Q27279564 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 56 (45.90) | 18.7374 |
| 1990's | 37 (30.33) | 18.2507 |
| 2000's | 14 (11.48) | 29.6817 |
| 2010's | 12 (9.84) | 24.3611 |
| 2020's | 3 (2.46) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (98.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (0.78%) | 5.53% |
| Reviews | 16 (12.40%) | 6.00% |
| Case Studies | 44 (34.11%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 68 (52.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl. | 1.96 | 1 | 0 | N-acylglycine | human blood serum metabolite; uremic toxin |
| iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge.. | 2.11 | 1 | 0 | diatomic iodine | nutrient |
| phytic acid Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated. | 1.96 | 1 | 0 | inositol phosphate | |
| cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. | 1.95 | 1 | 0 | piperidines; tertiary amine | anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist |
| pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium. | 2.65 | 3 | 0 | pentacarboxylic acid | copper chelator |
| mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. | 1.95 | 1 | 0 | diarylmethane | |
| corticosterone [no description available] | 2.01 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite |
| spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7. | 2.37 | 2 | 0 | 3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester | aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic |
| aldosterone [no description available] | 3.71 | 10 | 0 | 11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde | human metabolite; mouse metabolite |
| dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands. | 2.37 | 2 | 0 | 17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid | androgen; human metabolite; mouse metabolite |
| dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone. | 2.03 | 1 | 0 | 17-oxo steroid; steroid sulfate | EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite |
| selenomethionine [no description available] | 1.95 | 1 | 0 | selenoamino acid; selenomethionines | plant metabolite |
| metomidate metomidate: was heading 1975-94 (see under IMIDAZOLES 1975-90); METHOXIMOL was see METOMIDATE 1975-94; use IMIDAZOLES to search METOMIDATE 1975-94; a hypnotic and sedative that may also function as an anesthetic; now banned as an anesthetic for swine; C11-metomidate used as tracer for PET for adrenal neoplasms | 2.41 | 1 | 0 | imidazoles | |
| technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years. | 3.06 | 5 | 0 | manganese group element atom | |
| 3-iodobenzylguanidine 3-Iodobenzylguanidine: A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase. | 6.6 | 11 | 0 | organoiodine compound | |
| 18-hydroxydeoxycorticosterone 18-hydroxydeoxycorticosterone: structure given in first source | 2.01 | 1 | 0 | 18-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid | |
| fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162) | 2.52 | 2 | 0 | 2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose | |
| selenonorcholesterol selenonorcholesterol: adrenal radioisotope scanning agents | 3.75 | 3 | 0 | ||
| technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents. | 2.65 | 3 | 0 | ||
| pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups. | 1.96 | 1 | 0 | diphosphate ion | |
| etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity. | 2.41 | 1 | 0 | ethyl ester; imidazoles | intravenous anaesthetic; sedative |
| thallium Thallium: A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.. thallium : A metallic element first identified and named from the brilliant green line in its flame spectrum (from Greek thetaalphalambdalambdaomicronsigma, a green shoot). | 3.06 | 1 | 0 | boron group element atom | |
| indium Indium: A metallic element, atomic number 49, atomic weight 114.818, symbol In. It is named from its blue line in the spectrum.. indium atom : A metallic element first identified and named from the brilliant indigo (Latin indicum) blue line in its flame spectrum. | 1.96 | 1 | 0 | boron group element atom | |
| sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine. | 1.95 | 1 | 0 | chalcogen; nonmetal atom | macronutrient |
| selenium Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE. | 2.36 | 2 | 0 | chalcogen; nonmetal atom | micronutrient |
| technetium tc 99m pyrophosphate Technetium Tc 99m Pyrophosphate: A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. | 1.96 | 1 | 0 | ||
| 19-iodocholesterol 19-Iodocholesterol: 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | 4.31 | 6 | 0 | ||
| 6-iodomethylcholesterol 6-iodomethylcholesterol: RN given refers to (123)I-labeled cpd (3 beta,6 beta)-isomer | 1.96 | 1 | 0 | ||
| sodium pertechnetate tc 99m Sodium Pertechnetate Tc 99m: A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints. | 3.07 | 1 | 0 | ||
| rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | 2.21 | 1 | 0 | cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion | angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Aldosteronism [description not available] | 0 | 12.57 | 51 | 0 |
| Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. | 0 | 7.57 | 51 | 0 |
| Adenoma, Basal Cell [description not available] | 0 | 7.76 | 39 | 1 |
| Adenoma A benign epithelial tumor with a glandular organization. | 0 | 7.76 | 39 | 1 |
| Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. | 0 | 4.37 | 20 | 0 |
| Adenoma, Adrenal Cortical [description not available] | 0 | 3.51 | 8 | 0 |
| Adrenal Cortex Cancer [description not available] | 0 | 4.55 | 25 | 0 |
| Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX. | 0 | 4.55 | 25 | 0 |
| Blood Pressure, High [description not available] | 0 | 4.51 | 9 | 0 |
| Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. | 0 | 4.51 | 9 | 0 |
| Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) | 0 | 3.1 | 5 | 0 |
| Adrenal Cancer [description not available] | 0 | 9.53 | 37 | 1 |
| Cushing's Syndrome [description not available] | 0 | 7.8 | 31 | 0 |
| Complication, Postoperative [description not available] | 0 | 2.1 | 1 | 0 |
| Cancer, Second Primary [description not available] | 0 | 2.1 | 1 | 0 |
| Multiple Primary Neoplasms [description not available] | 0 | 2.91 | 4 | 0 |
| Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. | 0 | 7.8 | 31 | 0 |
| Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. | 0 | 2.1 | 1 | 0 |
| Carney Complex Autosomal dominant syndrome characterized by cardiac and cutaneous MYXOMAS; LENTIGINOSIS (spotty pigmentation of the skin), and endocrinopathy and its associated endocrine tumors. The cardiac myxomas may lead to SUDDEN CARDIAC DEATH and other complications in Carney complex patients. The gene coding for the PRKAR1A protein is one of the causative genetic loci (type 1). A second locus is at chromosome 2p16 (type 2). | 0 | 2.11 | 1 | 0 |
| Carcinoma, Anaplastic [description not available] | 0 | 2.89 | 4 | 0 |
| Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer. | 0 | 7.89 | 4 | 0 |
| Chronic Kidney Failure [description not available] | 0 | 2.07 | 1 | 0 |
| Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. | 0 | 2.07 | 1 | 0 |
| Adrenocortical Carcinoma A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM. | 0 | 2.03 | 1 | 0 |
| Pheochromocytoma, Extra-Adrenal [description not available] | 0 | 4.75 | 7 | 0 |
| Ectopic Hormone Syndromes [description not available] | 0 | 2.02 | 1 | 0 |
| Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) | 0 | 4.75 | 7 | 0 |
| Cancer of Ovary [description not available] | 0 | 3.21 | 6 | 0 |
| Androgenization [description not available] | 0 | 3.06 | 5 | 0 |
| Adrenal Cortical Rest Tumor [description not available] | 0 | 1.96 | 1 | 0 |
| Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. | 0 | 3.21 | 6 | 0 |
| Ectopic ACTH Syndrome [description not available] | 0 | 1.96 | 1 | 0 |
| ACTH Syndrome, Ectopic Symptom complex due to ACTH production by non-pituitary neoplasms. | 0 | 1.96 | 1 | 0 |
| Adrenal Cortex Diseases Pathological processes of the ADRENAL CORTEX. | 0 | 3.29 | 2 | 0 |
| Benign Neoplasms [description not available] | 0 | 1.96 | 1 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 1.96 | 1 | 0 |
| Bone Cancer [description not available] | 0 | 1.96 | 1 | 0 |
| Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. | 0 | 1.96 | 1 | 0 |
| Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). | 0 | 1.95 | 1 | 0 |
| Adrenal Gland Diseases Pathological processes of the ADRENAL GLANDS. | 0 | 6.99 | 20 | 0 |
| Hyperlipemia [description not available] | 0 | 1.95 | 1 | 0 |
| Hyperlipidemias Conditions with excess LIPIDS in the blood. | 0 | 1.95 | 1 | 0 |
| Elevated Cholesterol [description not available] | 0 | 1.95 | 1 | 0 |
| Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. | 0 | 1.95 | 1 | 0 |
| Bleeding [description not available] | 0 | 2.9 | 1 | 0 |
| Myelolipoma A rare benign tumor of the adrenal gland, several centimeters in diameter, composed in varying proportions of adipose tissue, lymphocytes, and primitive myeloid cells, probably a developmental abnormality. (Dorland, 27th ed) | 0 | 2.9 | 1 | 0 |
| Hemorrhage Bleeding or escape of blood from a vessel. | 0 | 2.9 | 1 | 0 |
| Cyst [description not available] | 0 | 2.66 | 3 | 0 |
| Infarct [description not available] | 0 | 1.99 | 1 | 0 |
| Cancer of Pituitary [description not available] | 0 | 1.99 | 1 | 0 |
| AIRE Deficiency [description not available] | 0 | 1.99 | 1 | 0 |
| Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. | 0 | 1.99 | 1 | 0 |
| Angio-Osteohypertrophy Syndrome [description not available] | 0 | 1.99 | 1 | 0 |
| Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. | 0 | 2 | 1 | 0 |
| Congenital Adrenal Hyperplasia [description not available] | 0 | 2.67 | 3 | 0 |
| Cancer of Testis [description not available] | 0 | 2.38 | 2 | 0 |
| Adrenal Hyperplasia, Congenital A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders. | 0 | 2.67 | 3 | 0 |
| Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms. | 0 | 2.38 | 2 | 0 |
| Germinoblastoma [description not available] | 0 | 2 | 1 | 0 |
| Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. | 0 | 7 | 1 | 0 |
| Angioma A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated. | 0 | 2 | 1 | 0 |
| Hemangioma A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000) | 0 | 2 | 1 | 0 |
| Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed) | 0 | 2.01 | 1 | 0 |
| Anterior Cervical Pain [description not available] | 0 | 2.01 | 1 | 0 |
| Back Ache [description not available] | 0 | 2.01 | 1 | 0 |
| Precordial Catch [description not available] | 0 | 2.01 | 1 | 0 |
| Back Pain Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions. | 0 | 2.01 | 1 | 0 |
| Chest Pain Pressure, burning, or numbness in the chest. | 0 | 2.01 | 1 | 0 |
| Flushing A transient reddening of the face that may be due to fever, certain drugs, exertion, or stress. | 0 | 2.01 | 1 | 0 |
| Neck Pain Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck. | 0 | 2.01 | 1 | 0 |
| Androblastoma [description not available] | 0 | 1.95 | 1 | 0 |
| Interstitial Cell Tumor [description not available] | 0 | 2.37 | 2 | 0 |
| Nelson Syndrome A syndrome characterized by HYPERPIGMENTATION, enlarging pituitary mass, visual defects secondary to compression of the OPTIC CHIASM, and elevated serum ACTH. It is caused by the expansion of an underlying ACTH-SECRETING PITUITARY ADENOMA that grows in the absence of feedback inhibition by adrenal CORTICOSTEROIDS, usually after ADRENALECTOMY. | 0 | 1.95 | 1 | 0 |
| Liver Dysfunction [description not available] | 0 | 1.95 | 1 | 0 |
| Pancreatic Diseases Pathological processes of the PANCREAS. | 0 | 1.95 | 1 | 0 |
| Splenic Diseases Diseases involving the SPLEEN. | 0 | 1.95 | 1 | 0 |
| Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. | 0 | 1.95 | 1 | 0 |
| Liver Diseases Pathological processes of the LIVER. | 0 | 1.95 | 1 | 0 |
| Adrenal Gland Hyperfunction [description not available] | 0 | 1.95 | 1 | 0 |
| Adrenocortical Hyperfunction Excess production of ADRENAL CORTEX HORMONES such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and/or ANDROSTENEDIONE. Hyperadrenal syndromes include CUSHING SYNDROME; HYPERALDOSTERONISM; and VIRILISM. | 0 | 1.95 | 1 | 0 |
| Gangliocytoma [description not available] | 0 | 1.98 | 1 | 0 |
| Hematoma A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue. | 0 | 1.98 | 1 | 0 |
| Calcification, Pathologic [description not available] | 0 | 2.89 | 1 | 0 |
| Atypical Lipoma [description not available] | 0 | 2.89 | 1 | 0 |
| Calcinosis Pathologic deposition of calcium salts in tissues. | 0 | 2.89 | 1 | 0 |
| Lipoma A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule. | 0 | 2.89 | 1 | 0 |
| Thyroid Diseases Pathological processes involving the THYROID GLAND. | 0 | 2.89 | 1 | 0 |
| Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) | 0 | 2.89 | 1 | 0 |
| Hirsutism A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth. | 0 | 1.97 | 1 | 0 |
| Ovarian Diseases Pathological processes of the OVARY. | 0 | 2.37 | 2 | 0 |
| Cancer of Lung [description not available] | 0 | 2.37 | 2 | 0 |
| Genito-urinary Cancer [description not available] | 0 | 1.97 | 1 | 0 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 2.37 | 2 | 0 |
| Urogenital Neoplasms Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female. | 0 | 1.97 | 1 | 0 |
| Parathyroid Disorders [description not available] | 0 | 2.88 | 1 | 0 |
| Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES. | 0 | 2.88 | 1 | 0 |
| Parathyroid Diseases Pathological processes of the PARATHYROID GLANDS. They usually manifest as hypersecretion or hyposecretion of PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body. | 0 | 2.88 | 1 | 0 |
| Adenocarcinoma Of Kidney [description not available] | 0 | 1.97 | 1 | 0 |
| Cancer of Kidney [description not available] | 0 | 1.97 | 1 | 0 |
| Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. | 0 | 1.97 | 1 | 0 |
| Kidney Neoplasms Tumors or cancers of the KIDNEY. | 0 | 1.97 | 1 | 0 |
| Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply. | 0 | 1.97 | 1 | 0 |
| Symptom Cluster [description not available] | 0 | 1.96 | 1 | 0 |
| Syndrome A characteristic symptom complex. | 0 | 1.96 | 1 | 0 |
| Cardiac Cancer [description not available] | 0 | 1.96 | 1 | 0 |